Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

November 12, 2021

Study Completion Date

November 12, 2021

Conditions
Asthma
Interventions
DRUG

Voriconazole Inhalation Powder

For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).

DRUG

Placebo

For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).

Trial Locations (1)

4006

Q-Pharm Pty Ltd (Nucleus Networks), Brisbane

All Listed Sponsors
lead

TFF Pharmaceuticals, Inc.

INDUSTRY

NCT04576325 - Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma | Biotech Hunter | Biotech Hunter